GlaxoSmithKline: Clinical Trials

4,953 trials sponsored by GlaxoSmithKline, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4010 completed, 375 terminated, 158 recruiting, 150 withdrawn. 1398 Phase 1, 1267 Phase 2, 1100 Phase 3, 539 Phase 4, 209 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 11398Completed 1140, Terminated 118, Withdrawn 49, Recruiting 37, Active not recruiting 32, Not yet recruiting 14, Unknown 7, Suspended 1
Phase 21267Completed 937, Terminated 146, Recruiting 61, Active not recruiting 47, Withdrawn 47, Unknown 16, Not yet recruiting 13
Phase 31100Completed 928, Terminated 64, Recruiting 46, Active not recruiting 22, Withdrawn 21, Unknown 12, Not yet recruiting 7
Phase 4539Completed 449, Terminated 36, Unknown 20, Withdrawn 17, Active not recruiting 7, Not yet recruiting 5, Recruiting 4, Enrolling by invitation 1
Not applicable209Completed 171, Terminated 14, Unknown 13, Withdrawn 6, Recruiting 3, Not yet recruiting 1, Suspended 1
Early Phase 116Completed 10, Active not recruiting 2, Recruiting 2, Terminated 2

Follow GlaxoSmithKline: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.
belantamab mafodotin to the existing stable standard background therapy - SLE - Systemic Lupus Erythematosus
Phase 2Not yet recruitingMedical Association for the Study of Cancer Biology and Treatment122027-02-012026-09-28
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial
Phase 1Not yet recruitingGlaxoSmithKline602027-01-252026-07-16
A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)
Ris-Rez, Atezolizumab, Etoposide - Lung Neoplasm
Phase 3Not yet recruitingGlaxoSmithKline7002026-12-252026-11-18
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer
Dostarlimab - Neoplasms, Rectal
Phase 3Not yet recruitingGlaxoSmithKline1002026-12-172026-11-16
B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants
Bepirovirsen - Hepatitis B
Phase 4Not yet recruitingGlaxoSmithKline3032026-12-032026-11-02
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM)
Phase 1Not yet recruitingCanadian Myeloma Research Group1082026-12-012026-09-21
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib - Multiple Myeloma
Phase 3RecruitingPrECOG, LLC.5002026-12-012026-11-12
A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors
RZV vaccine, Placebo - Cardiovascular Disease
Phase 3Not yet recruitingGlaxoSmithKline163902026-11-302026-10-13
A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours
GSK5864399 - Solid Tumours
Phase 1 / Phase 2Not yet recruitingGlaxoSmithKline1552026-11-252026-11-18
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial
Phase 3Not yet recruitingGlaxoSmithKline3782026-11-122026-10-19
A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib
Velzatinib - Healthy Participants, Gastrointestinal Neoplasms
Phase 1Not yet recruitingGlaxoSmithKline402026-11-102026-10-06
A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants
Bepirovirsen - Hepatitis B
Phase 1Not yet recruitingGlaxoSmithKline982026-11-032026-10-29
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF)
Phase 4Not yet recruitingSWOG Cancer Research Network2682026-11-012026-09-17
A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
GSK3862995B, GSK5784283, Placebo - Pulmonary Disease, Chronic Obstructive
Phase 2RecruitingGlaxoSmithKline2792026-10-292026-11-17
A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib
Velzatinib - Healthy Participants, Gastrointestinal Neoplasms
Phase 1Not yet recruitingGlaxoSmithKline302026-10-232026-10-09
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
Belantamab mafodotin, Bortezomib, Dexamethasone - Multiple Myeloma
Phase 1Not yet recruitingGlaxoSmithKline202026-10-232026-05-27
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events
Placebo, Adjuvanted RZV vaccine, Adjuvanted RSVPreF3 vaccine - Cardiovascular Disease
Phase 2Not yet recruitingGlaxoSmithKline4502026-10-232026-10-20
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20) - Multiple Myeloma
Phase 1Not yet recruitingGlaxoSmithKline222026-10-162026-08-03
A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants
Velzatinib, Cyclosporine, Omeprazole - Healthy Participants, Gastrointestinal Neoplasms
Phase 1Not yet recruitingGlaxoSmithKline362026-10-162026-10-07
A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
Velzatinib - Gastrointestinal Neoplasms
Phase 2Not yet recruitingGlaxoSmithKline722026-10-132026-09-28

Showing 20 of 4953. Sign in to see all of them.

Conditions studied

Pulmonary Disease, Chronic Obstructive (339)  ·  Asthma (314)  ·  Influenza, Human (200)  ·  Neoplasms (166)  ·  Hepatitis B (152)  ·  Diabetes Mellitus, Type 2 (151)  ·  Infections (146)  ·  Acquired Immunodeficiency Syndrome (133)  ·  HIV Infections (130)  ·  Breast Neoplasms (106)  ·  Tetanus (103)  ·  Diphtheria (98)  ·  Haemophilus Infections (83)  ·  Meningococcal Infections (78)  ·  Papillomavirus Infections (72)

Interventions

Lapatinib (115)  ·  Fluticasone (112)  ·  pazopanib (92)  ·  fluticasone furoate (71)  ·  Rosiglitazone (64)  ·  Data Collection (62)  ·  Fluticasone-Salmeterol Drug Combination (62)  ·  belimumab (60)  ·  dostarlimab (60)  ·  Topotecan (58)  ·  mepolizumab (58)  ·  dolutegravir (57)  ·  Blood Specimen Collection (55)  ·  Salmeterol Xinafoate (54)  ·  diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (54)

Countries

United States (2122)  ·  United Kingdom (819)  ·  Germany (720)  ·  Canada (627)  ·  Spain (519)  ·  France (451)  ·  Australia (414)  ·  Italy (379)  ·  Belgium (376)  ·  South Korea (347)  ·  Japan (343)  ·  Netherlands (335)  ·  Poland (317)  ·  Russia (299)  ·  Argentina (249)

Top investigators

Roger K Cady, MD (6)  ·  Anthony Greco, MD (4)  ·  Christian Tielemans, MD, PhD (3)  ·  David V Condoluci, DO (3)  ·  Evangelos Terpos, Prof (3)

Results publications

PMID 41276263, PMID 25387217, PMID 36005278, PMID 27881132, PMID 36472162, PMID 24314123, PMID 34628605, PMID 34741731, PMID 37781954, PMID 26704701, PMID 28683300, PMID 30954640, PMID 32710245, PMID 34473343, PMID 34531304, PMID 38775637, PMID 38780109, PMID 39115551, PMID 39208825, PMID 20526599, PMID 24408395, PMID 24443277, PMID 24918790, PMID 26446943, PMID 31824976, PMID 33687069, PMID 34098955, PMID 34523118, PMID 38216728, PMID 38724182, PMID 39377226, PMID 40190112, PMID 41461999, PMID 23054212, PMID 23254770, PMID 24731816, PMID 24966061, PMID 24998880, PMID 25424785, PMID 25424918, PMID 26873055, PMID 27093773, PMID 27796912, PMID 29465480, PMID 31047111, PMID 31164116, PMID 31197640, PMID 31251094, PMID 31302695, PMID 31321713

NIH funding

2016 (55), 2017 (51), 2023 (48), 2015 (41), 2025 (36), 2014 (31), 2018 (24), 2009 (22), 2008 (18), 2019 (14), 2004 (8), 2005 (7), K23HD045386 (2), P30CA138292 (2), U01AI065683 (2)